Project Main Details
Unlike other pasteurella vaccines, Nuplura utilizes recombinant technology to
provide a consistently pure and smooth vaccine, with a fast onset of immunity
in as soon as ten days.
Nuplura PH® consists of two virulence factors, recombinant leukotoxoids and outer membrane proteins. Novartis Elanco animal health has identified these factors as critical in developing the protection necessary against Mannheimia Haemolytica in beef and dairy cow.
Recombinant technology is used to create the leukotoxoid in Nuplura.
The process begins with the wild type leukotoxin gene of Mannheimia Haemolytica. In the natural infection that causes disease the expression of active wild type leukotoxin requires the entire gene to be present using recombinant technology, only a portion of the leukotoxin is used by inserting that portion into E. coli plasma DNA, thus forming recombinant gene.
As a result, all disease-causing properties are removed and a modern leukotoxoid antigen is born.
The new DNA containing the recombinant leukotoxoid gene then inserted into a laboratory adapted E. coli cell that produces the leukotoxoid as it multiplies during growth.
The leukotoxoid produced undergoes a proprietary purification process to discard the E. coli cells
and its unwanted proteins. The result is a safe and highly pure recombinant leukotoxoid.
The proprietary process requires no additional chemical inactivation so antigen quality and protective immunity are not compromised.
The other differentiating component have Nuplura PH® is outer membrane proteins. When outer membrane proteins are used as vaccine antigens they stimulate antibodies and facilitate bacterial cell death.
Using lab run Mannheimia Haemolytica cells and a proprietary process,
outer membrane proteins are extracted.
This eliminates the cellular debris, isolating the protective proteins that drive targeted immune response.
This results in the consistent blend leukotoxoid and outer membrane proteins
in every bottle to deliver a high level of consistent protection against Mannheimia Haemolytica.
The first vaccine if it's kind, Nuplura PH®, sets a new standard in cattle pnemonia prevention.
Voice123 Team Comments
Voice123 consultations with this voice seeker regarding this project and/or other projects by this voice seeker, via phone, chat, and/or email.
This project - phone.
Previous projects - phone.
This project - email or chat.
Previous projects - email or chat.
Corporate web site for this voice-seeker confirmed by Voice123
Note: Voice123 strives to establish the legitimacy of all projects posted. However, Voice123 subscribers and users are responsible for confirming information stated by prospective voice seekers, agents and/or clients. Voice123 subscribers and users assume all liability for use of any information found through Voice123, or any of its publications.
This page contains the most important details of this project. If you find the information on this project inaccurate or inappropriate, please let us know by contacting us.